Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications. (PubMed, J Cardiovasc Pharmacol) - Oct 10, 2026 - "However, topline results from the phase 3 Lp(a)HORIZON trial showed that pelacarsen, despite lowering Lp(a), did not reduce the primary composite cardiovascular endpoint. Full trial data are awaited, while four other phase 3 cardiovascular outcome trials - OCEAN(a)-Outcomes, ACCLAIM-Lp(a), MOVE-Lp(a), and OCEAN(a)-PreEvent - remain ongoing. Should positive outcome data emerge, clinical implementation will require regulatory approval, evidence-based patient selection, standardized treatment thresholds, and equitable access strategies across diverse populations."
Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • APOB
|
|
Alfredo Caturano; Alfredo Mauriello; Andrea Boccatonda; Carlo Acierno; Damiano D'Ardes; Davide Nilo; Vincenzo Russo
|